Study 2 of 9Pramlintide literatureNature metabolismTop journal2026
The story of amylin: from physiology to therapy.
Not reported in abstract.
Where it sits
this study against the rest of the pramlintide corpus4
Preclinical · this one
5
Observational
0
Open-label
0
Randomised
0
Reviews
Summary and findings
Not reported in abstract.
How much of this paper we could read: title only (0.10). The feed gave us little more than the title, so our summary is thin. This says nothing about the study's quality — read the source. What this means →
2026
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.
Elsewhere in the Pramlintide corpus
BReal-World EHR Signals from a Cohort of Blinded Incretin Trial Participants Motivate Novel Indication Opportunitiesbiorxiv-preprint · 2026 · -7.7% weight loss in masked CagriSema/placebo cohort vs -10.2% in tirzepatide, P=0.27HumanCOral delivery of the amylin receptor agonist pramlintidebiorxiv-preprint · 2023 · Oral delivery of microparticles showed a release duration of 120 min compared to 30 min for pramlintide in solution.AnimalCSexually dimorphic effects of Amylin 1 receptor activation in trigeminovascular neuronsbiorxiv-preprint · 2024 · Not reported in abstract.AnimalDAmylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?Lancet (London, England) · 2026 · Not reported in abstract.reviewBImmune pathways and prenatal/perinatal environmental exposures contribute to epigenetic gestational age prediction and acceleration.Epigenetics · 2026 · n=391 · R² = 0.88 for multi-CpG site model predictive accuracy.HumanCThe cyclin dependent kinase (CDK)7 inhibitor BS-181 inhibits pathogenic Cryptococcus species, causing G<sub>2</sub>/M arrest and a splicing defect.Virulence · 2026 · 2-4-fold reduction in the amphotericin B MIC with BS-181.Animal